Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients
出版年份 2021 全文链接
标题
Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients
作者
关键词
-
出版物
ALLERGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2021-08-31
DOI
10.1111/all.15071
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Immunological Properties of Atopic Dermatitis-Associated Alopecia Areata
- (2021) Reiko Kageyama et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The effectiveness of dupilumab in alopecia areata patients with atopic dermatitis: a case series of seven patients
- (2020) K. Harada et al. BRITISH JOURNAL OF DERMATOLOGY
- Alopecia Areata Is Associated with Atopic Diathesis: Results from a Population-Based Study of 51,561 Patients
- (2020) Khalaf Kridin et al. Journal of Allergy and Clinical Immunology-In Practice
- The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata
- (2020) Nekma Meah et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Cross-sectional study of blood biomarkers of patients with moderate-to-severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation
- (2020) Jacob W. Glickman et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
- (2020) Lisa A. Beck et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- JAK inhibitors and alopecia areata
- (2019) Amos Gilhar et al. LANCET
- JAK inhibitors for alopecia areata: a systematic review and meta-analysis
- (2019) Kevin Phan et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- (2019) E. Guttman-Yassky et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Association Between Alopecia Areata, Anxiety, and Depression: A Systematic Review and Meta-analysis
- (2019) Jean-Phillip Okhovat et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
- (2019) Claus Bachert et al. LANCET
- An Integrated model of Alopecia Areata biomarkers highlights both Th1/Th2 up-regulation
- (2018) Teresa Song et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- (2018) A. Jabbari et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The Utility and Validity of the Alopecia Areata Symptom Impact Scale in Measuring Disease-Related Symptoms and their Effect on Functioning
- (2018) Tito R. Mendoza et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS
- Treatment of alopecia areata: An Australian expert consensus statement
- (2018) William C Cranwell et al. AUSTRALASIAN JOURNAL OF DERMATOLOGY
- Hair Regrowth in a Patient With Long-standing Alopecia Totalis and Atopic Dermatitis Treated With Dupilumab
- (2018) Lauren R. Penzi et al. JAMA Dermatology
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- (2017) Lucy Y. Liu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Functional Interpretation of Genome-Wide Association Study Evidence in Alopecia Areata
- (2016) Lynn Petukhova et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
- (2016) Sally Wenzel et al. LANCET
- Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing
- (2015) Mayte Suárez-Fariñas et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- (2014) Luzhou Xing et al. NATURE MEDICINE
- CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials
- (2013) Kenneth F. Schulz ANNALS OF INTERNAL MEDICINE
- Lifetime Incidence Risk of Alopecia Areata Estimated at 2.1% by Rochester Epidemiology Project, 1990–2009
- (2013) Sultan A. Mirzoyev et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Diffuse alopecia areata is associated with intense inflammatory infiltration and CD8+ T cells in hair loss regions and an increase in serum IgE level
- (2012) Xingqi Zhang et al. Indian Journal of Dermatology Venereology & Leprology
- Follow-Up Study of the First Genome-Wide Association Scan in Alopecia Areata: IL13 and KIAA0350 as Susceptibility Loci Supported with Genome-Wide Significance
- (2012) Dagny Jagielska et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Quality of life in alopecia areata: a disease-specific questionnaire
- (2012) G. Fabbrocini et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- History of atopy or autoimmunity increases risk of alopecia areata
- (2009) Nazila Barahmani et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Subcutaneous efalizumab is not effective in the treatment of alopecia areata
- (2008) Vera H. Price et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started